Chemours Co
Chemours director Mary B. Cranston bought 6,000 shares of The Chemours Company (CC) on Aug. 7, 2026 at $15.825 each for $94,950. Post-trade, her beneficial ownership is 113,140.9469 shares. The article also cites Chemours Q2 results of $0.42 EPS on $1.59B revenue, and a UBS downgrade to Neutral with a $18 target from $29.
Chemours insider Michael Robert Foley, president of Titanium Technologies, bought 1,934.2313 shares of Chemours (NYSE:CC) on Aug. 7, 2026 for about $29,999 at $15.51 to $15.54 per share. The purchase follows Q2 2026 results of $0.42 EPS on $1.59B revenue, below estimates, and a UBS downgrade to Neutral with a $18 target.
Chemours (CC) launched ultra-low and low-GWP Opteon ZE (R-1234ze(E)) and Opteon 515B (R-515B) for stationary chillers and AI data center cooling. The article links the expansion to Chemours’ regulatory-driven refrigerant growth narrative but notes weak Opteon aftermarket demand, PFAS liabilities, and interest costs. It cites a 2026 net loss outlook of $255m to $230m and longer-term targets of $6.8b revenue and $1.3b earnings by 2029.
Over the past 7 days, alphai's AI scored 3 news stories mentioning CC (Chemours Co). Coverage has been balanced: 0 bullish, 3 neutral, and 0 bearish.
Recent CC coverage spans insider activity, financial news and technology.
In the last 30 days, CC insiders filed 6 SEC Form 4 transactions — 6 purchases ($459K) and no sales. The most active reporter was Cowan Alister with 1 filing.
The article adds an insider buy signal, but it is not large enough to override the cited earnings miss and UBS downgrade.
The article discloses a small insider buy by Chemours’ president, alongside recent earnings miss and a UBS downgrade.
Product expansion supports the longer-term regulatory-driven refrigerant thesis, but near-term earnings risk remains tied to weak Opteon aftermarket demand and losses.
This is a routine insider open-market purchase with no 10b5-1 plan disclosed, but it is not a fundamental catalyst.
Insider open-market buying by the CEO is a modest positive signal, but it is not a fundamental catalyst like earnings or guidance.
alphai scores every news story that mentions CC with an AI model for sentiment and relevance, and aggregates insider trades from Chemours Co's SEC EDGAR Form 4 filings. Figures refresh continuously.
Chemours director Mary B. Cranston bought 6,000 shares of The Chemours Company (CC) on Aug. 7, 2026 at $15.825 each for $94,950. Post-trade, her beneficial ownership is 113,140.9469 shares. The article also cites Chemours Q2 results of $0.42 EPS on $1.59B revenue, and a UBS downgrade to Neutral with a $18 target from $29.
3 min readChemours insider Michael Robert Foley, president of Titanium Technologies, bought 1,934.2313 shares of Chemours (NYSE:CC) on Aug. 7, 2026 for about $29,999 at $15.51 to $15.54 per share. The purchase follows Q2 2026 results of $0.42 EPS on $1.59B revenue, below estimates, and a UBS downgrade to Neutral with a $18 target.
2 min readChemours (CC) launched ultra-low and low-GWP Opteon ZE (R-1234ze(E)) and Opteon 515B (R-515B) for stationary chillers and AI data center cooling. The article links the expansion to Chemours’ regulatory-driven refrigerant growth narrative but notes weak Opteon aftermarket demand, PFAS liabilities, and interest costs. It cites a 2026 net loss outlook of $255m to $230m and longer-term targets of $6.8b revenue and $1.3b earnings by 2029.
6 min readFamiliar Calderon Gerardo (See Remarks) purchased 1,935 shares of Chemours Co (CC) at $15.53 on 2026-08-12.
1 min readDignam Denise (Chief Executive Officer) purchased 3,378 shares of Chemours Co (CC) at $14.95 on 2026-08-11.
2 min readCowan Alister purchased 13,000 shares of Chemours Co (CC) at $15.62 ($0.20M total) on 2026-08-07.
2 min readMartinko Joseph T. (See Remarks) purchased 1,940 shares of Chemours Co (CC) at $15.47 on 2026-08-07.
2 min readCRANSTON MARY B purchased 6,000 shares of Chemours Co (CC) at $15.82 on 2026-08-07.
1 min readChemours Inc., its affiliates, and DuPont Industrial Biosciences USA LLC said a North Carolina resident’s proposed class action over PFAS contamination of Brunswick County water was dismissed, according to the filing. The dismissal was attributed to lack of fiduciary duty. The case outcome may affect potential liabilities for the companies.
2 min readHOSTETTER SHANE (Chief Financial Officer) purchased 3,350 shares of Chemours Co (CC) at $14.94 on 2026-08-06.
1 min read